2BB score and signals
Cardiff Oncology, Inc.’s current 2BB score is 26 out of 100, built from the signal categories below.
| Signal | Score | Reading |
|---|
| Activity | 0 | Very Low |
| Momentum | 17 | Strongly Weakening |
| Financial strength | 12 | Very Weak |
| Quality | 60 | Strong |
| Risk | 50 | Moderate |
Company facts
| CEO | Mark Erlander |
| Founded | 1999 |
| Employees | 31 |
| 52-week range | $0.76 – $3.30 |
Recent earnings
| Report date | EPS actual | EPS estimate | Revenue actual | Revenue estimate |
|---|
| 2027-02-22 | — | -0.1632 | — | $84,996.00 |
| 2026-11-04 | — | -0.1574 | — | $80,753.00 |
| 2026-07-30 | — | -0.1645 | — | $72,124.00 |
| 2026-05-14 | -0.18 | -0.1373 | $41,000.00 | $86,700.00 |
Related companies
2BBBullish & Bearish